The Ebmt company information, Employees & Contact Information

EBMT Unveils 2025 Clinical Practice Guidelines for Hematopoietic Cell Transplantation and CAR-T Therapy Bioengineer.org

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT | Bone Marrow Transplantation Nature

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT Nature

Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantati Frontiers

Visions for a JACIE Quality Management System 4.0 Nature

Half a century of healing: celebrating the 50th anniversary of EBMT Nature

The first steps towards a diverse and inclusive EBMT: a position paper Nature

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group – Oral Session (O160-O163) | Bone Marrow Transplantation Nature

Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT Nature

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey Nature

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P601- P606) | Bone Marrow Transplantation Nature

The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium – Poster Session Nature

Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey Nature

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients | Blood Cancer Journal Nature

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (ID Nature

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accre Nature

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the Nature

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations Nature

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement | Bone Marrow Transplantation Nature

Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT Nature

Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties Frontiers

EHA-EBMT 7th European CAR T-cell Meeting Oncodaily

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors Nature

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation Nature

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT Journal of Hematology & Oncology